Clinical trials: Oral Phase
Healthy
A Study Comparing Four Different Rivoceranib Tablets in Healthy Participants
The main purpose of this trial is to compare a single dose of 4 different rivoceranib tablets in healthy adult participants.
- Trial name
- NCT05287360
- Testing
- Rivoceranib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Elevar Therapeutics
Colorectal Neoplasms
Study to Evaluate the Effects of Panitumumab if Combined With Chemotherapy for 2nd Treatment of Colorectal Cancer
The purpose of this interventional study is to investigate whether there is evidence that panitumumab in combination with XELOX (capecitabine plus oxaliplatin) chemotherapy will safely increase progression-free survival, above…
- Trial name
- VOXEL (NCT00950820)
- Testing
- Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine
- Where
- Germany
- Volunteers
- 9 people
- Sponsor
- AIO-Studien-gGmbH
Healthy Subjects
PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults
Oral dosage regimens for fosfomycin tromethamine (Monurol™) are not established for the treatment of cUTI. The most common and recommended adult dosage regimen in the literature is a single-dose sachet containing the equivalent…
- Trial name
- PROOF (NCT02570074)
- Testing
- Fosfomycin
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Vance Fowler, M.D.
Parkinson Disease, Depression
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize…
- Trial name
- NCT00297778
- Testing
- Pramipexole
- Where
- 77 sites in Austria, Finland and 11 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Down Syndrome
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4 weeks.
- Trial name
- DS201 (NCT01791725)
- Testing
- ELND005
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- OPKO Health, Inc.
Healthy Volunteers
An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)
The primary objective of Part 1 of this study is to evaluate the safety and tolerability of the intravenous (IV) dose of GDC-0973.
- Trial name
- NCT01249118
- Testing
- GDC-0973 IV Infusion, GDC-0973 Oral Capsules
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Thromboembolism, Arthroplasty, Replacement, Hip
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in…
- Trial name
- NCT00168818
- Testing
- dabigatran etexilate, enoxaparin
- Where
- 116 sites in Australia, Austria and 14 more
- Volunteers
- 3,494 people
- Sponsor
- Boehringer Ingelheim
Anal Cancer, Cervical Cancer
Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer
RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in treating patients…
- Conditions
- Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer
- Trial name
- NCT00019110
- Testing
- human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
- Where
- 6 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma
The purpose of this study is to investigate on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation
- Trial name
- NCT02210182
- Testing
- Oral Pentamidine
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Oncozyme Pharma Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT01399840
- Testing
- BMN 673
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
Healthy Participants, Healthy Subjects
Study to Learn How Different Forms of The Study Medicine Called Danuglipron Are Taken up Into the Blood In Healthy Adults
The purpose of the study is to learn how different forms of a study medication called danuglipron are taken into the blood in healthy adults, following single dose administration.
- Trial name
- NCT06153758
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infection, Multiple Myeloma
Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients with multiple myeloma and may improve their response to chemotherapy.
- Trial name
- NCT00002850
- Testing
- ciprofloxacin, ofloxacin, 160 mg trimethoprim and 800 mg sulfamethoxazole
- Where
- 45 sites in United States, Peru and 1 more
- Volunteers
- 212 people
- Sponsor
- Gary Morrow
Invasive Aspergillosis
Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects
A Phase I, open label study evaluating safety, tolerability and pharmacokinetics of F901318 in healthy subjects following up to 28 days dosing, where F901318 is given orally .
- Trial name
- NCT03340597
- Testing
- F901318
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- F2G Ltd
Xerostomia Due to Hyposecretion of Salivary Gland
Chamomile Effect on Xerostomia Associated With End-stage Renal Disease in Elderly
Background and Objectives: Chronic hemodialysis causes changes in blood chemistry as well as dry mouth, due to removal of excess fluids. Dry mouth is due to hyposalivation or change in saliva composition.
- Trial name
- NCT06114797
- Testing
- Chamomile, Saline mouthwash
- Where
- Egypt
- Volunteers
- 88 people
- Sponsor
- Ain Shams University
Healthy Adult Participants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need.
- Trial name
- NCT05735249
- Testing
- ARN-75039 oral capsules
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Arisan Therapeutics, Inc.
Contraception
Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle
We hypothesize that administration of OCs at varying follicular diameters will provide an appropriate model for the study of follicular atresia in women.
- Trial name
- NCT00204438
- Testing
- 0.15mg desogestrel /0.03mg ethinyl estradiol
- Where
- Canada
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan
Unspecified Adult Solid Tumor, Protocol Specific
Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006047
- Testing
- Oral Etoposide, Oral 9-Nitrocamptothecin
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Healthy
[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study
[14C]PRC-4016 (Icosabutate) - A Phase I, Open-Label Study of the Absorption, Metabolism and Excretion Following Oral Dosing to Healthy Male Subjects.
- Trial name
- NCT02373176
- Testing
- [14C]PRC 4016 (Icosabutate)
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Pronova BioPharma
Recurrent Glioblastoma Multiforme
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
- Trial name
- NCT00481455
- Testing
- Panzem NCD, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CASI pharmaceuticals, Inc.
Hand, Foot and Mouth Disease (HFMD), HFMD
Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent Vaccine
This is a randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine in subjects ( aged 6…
- Conditions
- Hand, Foot and Mouth Disease (HFMD), HFMD, Hand, Foot and Mouth Disease
- Trial name
- NCT07326878
- Testing
- Low Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell), Medium Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell), High Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell)
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.